ceh-19 Antibody

What methodologies are used to isolate neutralizing antibodies from convalescent patients?

Neutralizing antibodies are typically isolated through single B-cell sorting and sequencing from patient samples. For example, researchers have successfully isolated potent neutralizing monoclonal antibodies (mAbs) from COVID-19 convalescent patients using this approach. The process involves collecting blood samples from patients who have recovered from viral infections, isolating B cells, and then performing single-cell sorting to identify cells producing antibodies of interest. This is followed by sequencing of antibody genes and expression of recombinant antibodies for functional testing . In some cases, computational pipelines are employed to select antibodies with potential cross-neutralizing ability from hundreds of antibody sequences. This approach has successfully identified broadly neutralizing antibodies against SARS-CoV-2 variants and related sarbecoviruses .

How is antibody binding specificity determined in experimental settings?

Antibody binding specificity is typically assessed through multiple complementary approaches. Researchers commonly employ enzyme-linked immunosorbent assays (ELISA) to measure binding affinity and examine competition between monoclonal antibodies and known reference antibodies . Additionally, flow cytometry-based binding assays (FACS) are utilized to evaluate the ability of antibodies to block interactions between viral receptor-binding domains (RBD) and cell surface receptors like ACE2 . For more detailed characterization, competition assays using techniques such as biolayer interferometry (Octet) provide insights into binding kinetics and epitope mapping . These methods collectively help determine whether antibodies bind specifically to target antigens and compete with natural ligands or other antibodies for binding sites.

What are the key metrics for evaluating neutralization potency of antibodies?

The neutralization potency of antibodies is primarily quantified through neutralization assays using both pseudovirus and live virus systems. The 50% neutralization dose (ND50) is a critical metric, representing the antibody concentration required to neutralize 50% of virus infectivity. Lower ND50 values indicate higher potency. For example, the monoclonal antibody CB6 demonstrated superior neutralizing activity against SARS-CoV-2 with an ND50 of 0.036 ± 0.007 μg/ml in Vero E6 cells compared to CA1's ND50 of 0.38 μg/ml . Neutralization assays are typically conducted in multiple cell lines to ensure robustness of results. For SARS-CoV-2 studies, researchers have used Huh7, Calu-3, HEK293T, and Vero E6 cells . Additionally, breadth of neutralization against variant strains is increasingly important for evaluating antibody therapeutics against evolving viruses.

How do researchers determine appropriate in vivo models for antibody testing?

Selection of appropriate animal models for in vivo antibody testing requires careful consideration of various factors. For SARS-CoV-2 antibody research, rhesus macaques have proven valuable as they closely mimic human physiology and immune responses. When designing in vivo studies, researchers typically establish both prophylactic and treatment protocols to evaluate protective efficacy. For instance, macaques can be divided into pre-exposure, post-exposure, and negative-control groups to assess both preventive and therapeutic potential . Viral load measurements from clinical samples (such as throat swabs) over consecutive days provide quantitative data on antibody efficacy. Researchers also perform necropsy and histopathological analyses to evaluate tissue damage and potential adverse effects, including the risk of antibody-dependent enhancement . These comprehensive evaluations help determine if antibodies can safely transition to human clinical trials.

What are the patterns of anti-chemokine antibodies following viral infections?

Anti-chemokine antibodies exhibit distinct patterns following viral infections like COVID-19, with significant implications for disease progression. Research has shown that antibodies against specific chemokines, including CCL19, CCL22, and CXCL17, emerge during infection and persist for months after recovery . The temporal evolution of these antibodies varies - some increase over time (CCL19, CCL8, CCL13, CCL16, CXCL7, and CX3CL1), while others remain stable (CXCL17) or follow variable kinetics (CCL22) . Interestingly, patients with different disease severities display distinct anti-chemokine antibody profiles. Outpatients typically show a broader pattern and higher cumulative anti-chemokine reactivity compared to hospitalized individuals, suggesting these antibodies may be associated with favorable disease outcomes . Methodologically, these patterns are detected using peptide-based strategies that measure antibodies binding to functional regions of human chemokines, particularly targeting the N-terminal loop (N-loop) which is required for receptor binding .

What computational approaches facilitate screening of cross-reactive antibodies?

Advanced computational approaches have significantly enhanced the identification of cross-reactive antibodies. One sophisticated pipeline combines multiple computational tools to screen potential cross-reactive antibodies from sequencing data. For example, researchers have employed the conformational epitope-basic local alignment search tool (CE-BLAST) to screen thousands of real and virtual epitopes of coronavirus spike proteins . This approach identified 132 potential cross-reactive epitopes from over 10,000 candidates. Following epitope identification, the patch model of SEPPA-mAb was applied to rank binding scores between cross-reactive epitopes and antibody complementarity-determining regions (CDRs) through structure complementarity calculations . This computational ranking enabled researchers to prioritize 86 top-ranking monoclonal antibodies for experimental validation. Such computational approaches substantially accelerate the discovery process by narrowing down candidate antibodies from hundreds to those most likely to exhibit cross-reactivity, thereby reducing the resources needed for empirical testing.

How do structural studies inform the mechanism of antibody neutralization?

Structural studies, particularly cryo-electron microscopy (cryo-EM), provide crucial insights into antibody neutralization mechanisms at the molecular level. By determining high-resolution structures of antibody-antigen complexes, researchers can visualize precisely how antibodies interfere with viral infection. For example, structural analysis of the CB6 antibody bound to the SARS-CoV-2 receptor-binding domain (RBD) revealed that CB6 recognizes an epitope that overlaps with angiotensin-converting enzyme 2 (ACE2)-binding sites . This structural information elucidated that CB6 employs dual mechanisms to prevent viral entry: steric hindrance and direct competition for interface residues . Both the heavy chain and light chain of CB6 create structural clashes with the receptor, effectively preventing ACE2 binding to the viral RBD. Such detailed structural knowledge is invaluable for rational design of antibody therapeutics and understanding resistance mechanisms that might emerge through viral mutations affecting the antibody binding site.

What methodologies are employed to evaluate the risk of antibody-dependent enhancement?

Antibody-dependent enhancement (ADE) poses a significant safety concern for antibody therapeutics against viral infections. To mitigate this risk, researchers employ multiple complementary approaches. In vitro studies assess whether sub-neutralizing concentrations of antibodies enhance viral infection in cell lines expressing Fc receptors. For in vivo evaluation, animal models are carefully monitored for signs of exacerbated disease following antibody administration, with particular attention to inflammatory markers and histopathological examination of affected tissues . At the molecular level, researchers have developed engineered antibodies with modifications to the Fc portion to eliminate ADE risk. For example, the LALA mutations introduced to the Fc portion of the CB6 antibody eliminated antibody-dependent cellular cytotoxicity effects while preserving neutralizing capacity . This modified antibody (CB6-LALA) demonstrated protective effects in rhesus monkeys without exacerbating tissue damage, providing a safer therapeutic candidate. Such modifications represent a critical methodological approach for developing antibody therapeutics with improved safety profiles.

How are antibody combinations evaluated for enhanced breadth and potency?

Evaluation of antibody combinations involves systematic assessment of complementary binding properties and synergistic neutralization effects. Researchers typically begin by characterizing individual antibodies for their binding epitopes, neutralization potency, and breadth against variant strains. Competition assays using ELISA or biolayer interferometry determine whether antibodies compete for the same epitope or bind to distinct sites . Non-competing antibodies targeting different epitopes are then combined at various ratios to assess potential synergistic effects. Neutralization assays using pseudovirus or live virus systems quantify improvements in breadth and potency compared to individual antibodies. For example, antibodies that neutralize different subsets of viral variants may be combined to create a cocktail with broader coverage. Additionally, combinations of antibodies targeting different vulnerable sites on viral proteins may provide higher barriers to escape mutations. This systematic approach has been employed successfully for developing therapeutic antibody combinations against SARS-CoV-2 and other viral pathogens.

What is the relationship between anti-chemokine antibodies and long-term disease outcomes?

The relationship between anti-chemokine antibodies and long-term disease outcomes represents an emerging area of research with important clinical implications. Longitudinal studies tracking patients over extended periods have revealed significant associations between anti-chemokine antibody profiles and long-term sequelae. For instance, research on COVID-19 patients demonstrated that specific anti-chemokine antibody patterns at 6 months post-infection were predictive of the absence of long COVID symptoms at one year . Detailed cohort studies have shown that approximately 65.1% of COVID-19 survivors report persistence of at least one symptom related to their infection at 12 months, with formerly hospitalized individuals experiencing a higher symptom burden than outpatients (72.7% versus 47.4%) . Methodologically, researchers compare anti-chemokine antibody levels between individuals with and without persistent symptoms while controlling for confounding factors such as age, gender, and time from disease onset. Multivariate analysis further helps identify which specific anti-chemokine antibodies serve as the strongest predictors of favorable long-term outcomes, potentially informing both prognostic tools and therapeutic strategies.

What are the key design elements of clinical trials for antibody therapeutics?

Clinical trials for antibody therapeutics require careful design considerations to efficiently evaluate safety and efficacy. Phase 2 trials typically focus on patients with mild to moderate disease not requiring hospitalization, as exemplified by the ACTIV-2 trial for COVID-19 therapeutics . These trials employ rigorous randomized, placebo-controlled designs to generate reliable data. A key innovative approach in antibody clinical trials is the adaptive design, which allows for seamless transition from Phase 2 to Phase 3 if preliminary results show promise, enabling researchers to gather critical data from larger volunteer pools without delay . This approach was implemented in trials sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) through the AIDS Clinical Trials Group (ACTG) . Such adaptive designs are particularly valuable during public health emergencies when rapid development of therapeutics is crucial. Additionally, clinical trials for antibody therapeutics must include comprehensive safety monitoring, especially for potential immunological adverse events, and collect samples for pharmacokinetic analyses to understand antibody distribution and clearance in humans.

How do researchers translate in vitro neutralization data to in vivo efficacy predictions?

Translating in vitro neutralization data to predictions of in vivo efficacy involves complex considerations of multiple factors. While neutralization potency (measured as ND50 or IC50) provides a starting point, researchers must account for pharmacokinetic parameters that influence antibody concentrations at sites of infection. Animal models serve as critical bridges between in vitro and human studies. For example, rhesus macaque models have demonstrated that potent neutralizing antibodies like CB6 can provide protection in both prophylactic and therapeutic settings against SARS-CoV-2 infection . When designing dosing regimens for clinical trials, researchers typically incorporate safety margins based on the minimum effective concentration observed in animal studies. Mathematical modeling approaches that integrate in vitro potency, pharmacokinetic data, and target tissue distribution help predict appropriate dosing regimens for humans. Additionally, researchers consider the durability of protection needed and the half-life of the antibody in circulation. For some applications, antibody engineering techniques such as Fc modifications can extend half-life, potentially reducing dosing frequency in clinical settings.